Table 1 Patient characteristics in this study
Median (range) or n (%) | Abiraterone (n = 34) | Enzalutamide (n = 32) | P-value |
|---|---|---|---|
Age | 75 (63–93) | 75 (51–95) | 0.52 |
Initial PSA | 87 (6–10,800) | 112 (6–10,800) | 0.67 |
PSA prior to each agent | 42 (3–3553) | 13 (0.5–3043) | 0.42 |
Gleason score | |||
≤ 6: 7: 8: ≥ 9: unknown | 4:5:4:19:2 | 2:7:4:18:1 | 0.91 |
T stage | |||
≤ T2: T3: T4 | 24:8:2 | 24:6:2 | 0.89 |
N1 | 13 (38) | 13 (40) | 0.84 |
M1 | 18 (53) | 17 (50) | 0.98 |
Line | |||
1st: 2nd: 3rd: 4th: 5th | 7:11:9:6:1 | 8:14:7:3:0 | 0.63 |
Chemotherapy history prior to each agent | 11 (32) | 10 (31) | 0.92 |
Flutamide effective as second-line | 15 (44) | 15 (47) | 0.82 |